Navigation Links
Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients
Date:10/26/2008

8th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/Infectious Diseases Society of America (IDSA) 46 Annual Meeting; Oct. 25-28, 2008; Washington, D.C., USA; No. H-1269.

(3) Zingman B, Suleiman J, DeJesus E, et al. Vicriviroc, a next generation CCR5 antagonist, exhibits potent, sustained suppression of viral replication in treatment-experienced adults: VICTOR-E1 48-week results. 15th Conference on Retroviruses and Opportunistic Infections (CROI); Feb. 3-6, 2008; Boston, MA, USA; Abstract 39LB.

(4) Gulick RM, Su Z, Flexner C, et al. Phase 2 Study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients: AIDS Clinical Trials Group 5211. J Infect Dis. 2007;196:304-312.

(5) Hoffmann C (2007) The epidemiology of HIV coreceptor tropism. Eur J Med Res (2007) 12: 385-390.

(6) Atazanavir sulfate is a Bristol-Myers Squibb Company prescription medicine. Please see the atazanavir product insert for information on this product.

(7) Truvada is a registered trademark of Gilead Sciences, Inc. Please see the Truvada product insert for information on this product.

(8) Data collection on adverse events of anti-HIV drugs (DAD) study group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349: 1993-2003.

(9) The DAD study group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356: 1723-35.

(10) The DAD study group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the DAD study: a multi-cohort collaboration. http://www.thelancet.com published online April 2, 2008, DOI:10.1016/S0140-6736(08)60423-7.


'/>"/>
SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
3. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
4. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
5. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
6. New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
7. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
8. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
9. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
10. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
11. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014  Decision Resources Group ... infectious disease (ID) specialists are willing to prescribe ... (oritavancin) for use as OPAT, approximately two-thirds of ... agents to their hospital inpatients. However, our findings ... patients are initiated on OPAT following hospital discharge, ...
(Date:7/10/2014)... Decision Resources Group finds that over half ... and Drug Administration,s (FDA) approval of Vifor Fresenius Medical ... approved by the FDA in November 2013 for the ... on dialysis. Other key findings from the ... : , Bundling: ...
(Date:1/15/2014)... , Jan. 15, 2014 Most osteoporosis patients want ... a recent online survey* sponsored by Mission Pharmacal Company. ... National Osteoporosis Foundation online support community, revealed that 74 ... that comes in a form other than a pill ...
Breaking Medicine Technology:Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3
... Varian Medical Systems (NYSE: VAR ) ... U.S. Customs and Border Protection (CBP) for multiple IntellX® cargo ... company,s largest single order for Varian,s IntellX gantry systems. The ... vehicles for both border security and manifest verification purposes. ...
... 2011 DURECT Corporation (Nasdaq: DRRX ) ... (FDA) has accepted the resubmission of the New Drug ... KG ) and the PDUFA goal date ... ) REMOXY, based on DURECT,s ORADUR® technology, ...
Cached Medicine Technology:Varian Medical Systems' Security and Inspection Products Group Receives Largest Single Order for IntellX Systems 2REMOXY® New Drug Application Accepted by the FDA with PDUFA Goal Date of June 23, 2011 2REMOXY® New Drug Application Accepted by the FDA with PDUFA Goal Date of June 23, 2011 3
(Date:7/11/2014)... reports that tickets to the Argentina vs. Germany World ... Brazil and Netherlands are in high demand. The ... at Estadio Nacional de Brasilia Mane Garrincha Brasila, Federal District. ... 13th at Estadio Jornalista Mario Filho - Estadio do Maracana, ... are guaranteed to be authentic and are covered by Ticket ...
(Date:7/11/2014)... 11, 2014 Butler Mobility has recently updated ... Platform Lifts . Previously the two standard colors were ... beautiful earth tone colors as standard colors at no additional ... the home but will enhance the beauty of the stairway. ... home color scheme or individual décor. , The new selection ...
(Date:7/11/2014)... (HealthDay News) -- People with the lowest incomes may have ... disease (PAD), a new study suggests. People with PAD ... limbs, most often the legs. The condition causes leg pain ... throughout the body. People with PAD have a higher risk ... nearly 6,800 people with PAD who took part in the ...
(Date:7/11/2014)... Volunteers from Scientology Churches ... week with drug education lectures, forums and conferences, information ... cities around the world. , Drug abuse is an ... Drug Abuse, abuse of alcohol and illicit drugs costs ... work, decreased productivity and healthcare. , In the ...
(Date:7/11/2014)... As part of its morcellator ... has been closely monitoring the ongoing meeting of ... Obstetrics and Gynecology Devices Panel, which has been ... risks associated with the use of power morcellators ... report published by Dow Jones Business News, a ...
Breaking Medicine News(10 mins):Health News:Argentina vs. Germany World Cup Finals Tickets & Brazil vs. Netherlands 3rd Place World Cup Tickets Are in Huge Demand 2Health News:Butler Mobility Products Announces Five New Standard Colors for Their Inclined Platform Lifts 2Health News:Poor More Prone to Leg Circulation Trouble 2Health News:Scientologists Taking Action against Drug Abuse 2Health News:Scientologists Taking Action against Drug Abuse 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 4
... chair to support efforts to address the rising ... in Maryland BALTIMORE, April 10 Richard H. ... General (2002-2006) and President of the non-profit Canyon ... elected Chairman of the Pharmaceutical Research and Manufacturers ...
... scientific article is cited by other articles is currently the ... measure: the number of unique downloads. , A recent ... that downloads are a good predictor of citations and ... in an editorial by Journal of Vision (JOV) ...
... 14-17, 2009, Underwriters Laboratories Inc.,s (UL) Primary Designated ... Manager Jola Wroblewska will present International Electrotechnical Committee ... (IECEE) CB Test Laboratories and National Certification Bodies ... promote common application of the guidelines prepared by ...
... April 10 Rheumatoid arthritis (RA) is a systemic ... defense system attacks the joints through the thin layer ... the joints. The most visible symptoms of RA are ... and feet. It can cause fatigue, fever, loss of ...
... eye physicians recommends , sport-specific eyewear to prevent devastating ... what started out as a routine basketball game his senior ... was a young basketball star who played years of hoops ... the eye by a teammate, Stephen ended up with a ...
... for skin appearance in 3 trials , , THURSDAY, April 9 ... to improve the healing of skin scars, according to three ... administered to their skin before wounding and again 24 hours ... the way through the skin of the upper inner arm ...
Cached Medicine News:Health News:National Health Experts to Announce Creation of Bipartisan Coalition to Fight Maryland's Growing Burden of Chronic Disease Tuesday at Inner Harbor 2Health News:UL Medical Experts to Provide Instruction on Guidance for Risk Management in IEC 60601-1:2005 at IECEE Workshop 2Health News:Rheumatoid Arthritis Therapeutics in Taiwan 2Health News:Rheumatoid Arthritis Therapeutics in Taiwan 3Health News:Eye Protection is Essential for Texas Athletes 2Health News:Eye Protection is Essential for Texas Athletes 3Health News:Medication May Improve Scar Healing 2
They employ Lea Symbols. Contrast levels are the same at 25%, 10%, 5%, 2.5% and 1.25%. Each offers a different set of Lea Symbols to guard against memorization. Also uses recording forms (P/N 215400)...
Symbol 10' Test Chart 10/100 to 10/10 size. 9" x 14"....
Wilbrandt-binkhorst irrigating cannula....
Binkhorst, length 35 mm....
Medicine Products: